An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study)).
Observational
Observational Model: Cohort, Time Perspective: Prospective
Distribution of patients receiving unique treatment regimen/sequence of treatment regimens
Up to 8 years
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
ML28257
NCT01615068
June 2012
December 2020
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
New Britain, Connecticut 06052 | |
Bettendorf, Iowa 52722 | |
Alexandria, Minnesota 56308 | |
Albany, Georgia 31701 | |
Great Falls, Montana 59405 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Flint, Michigan 48532 | |
Louisville, Kentucky 40207 | |
McLean, Virginia 22101 | |
Little Rock, Arkansas 72205-7199 | |
Kansas City, Kansas 66160 | |
Scarborough, Maine 04074 | |
Omaha, Nebraska 68114 | |
Hackensack, New Jersey 07601 | |
Metairie, Louisiana 70006 | |
Denver, Colorado | |
Baltimore, Maryland 21287 | |
Charlotte, North Carolina | |
Milwaukee, Wisconsin | |
Indianapolis, Indiana | |
Charleston, South Carolina | |
Lebanon, New Hampshire | |
Tulsa, Oklahoma | |
Charleston, West Virginia 25304 | |
Washington, District of Columbia |